GENE Positioned at the Forefront of Multi-cancer Clinical Utility Research – MRFF Grant names GTG as sole Industry Partner
Trial to Assess Multi Cancer Genetic Risk Assessment in General Practice MELBOURNE, Australia, Sept. 11,…
Year: 2023
GENE Positioned at the Forefront of Multi-cancer Clinical Utility Research – MRFF Grant names GTG as sole Industry Partner
Trial to Assess Multi Cancer Genetic Risk Assessment in General Practice MELBOURNE, Australia, Sept. 11,…
Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development
Evaxion is the first organization to validate an AI model that outcompetes state-of-the-art vaccine development…
Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development
Evaxion is the first organization to validate an AI model that outcompetes state-of-the-art vaccine development…
Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
SAN DIEGO, Sept. 11, 2023 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech…
Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
SAN DIEGO, Sept. 11, 2023 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech…
MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults
MBX 2109 was observed to be generally well-tolerated MBX 2109 increased albumin adjusted serum calcium…
MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults
MBX 2109 was observed to be generally well-tolerated MBX 2109 increased albumin adjusted serum calcium…
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
Post-hoc analysis from Phase 1b/2a study in pulmonary sarcoidosis presented at the European Respiratory Society…
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
Post-hoc analysis from Phase 1b/2a study in pulmonary sarcoidosis presented at the European Respiratory Society…
Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer
Company to present BDTX-1535 dose escalation data in NSCLC at the AACR-NCI-EORTC Conference in October…
Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer
Company to present BDTX-1535 dose escalation data in NSCLC at the AACR-NCI-EORTC Conference in October…
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform
Proof-of-concept manufacturing to be provided by Cellares for a key Lyell CAR T-cell therapy using…
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform
Proof-of-concept manufacturing to be provided by Cellares for a key Lyell CAR T-cell therapy using…
Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting
SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc….
Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting
SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc….
Results From Mayo Clinic Clinical Study of Humacyte’s Human Acellular Vessel™ (HAV™) in Treatment of Patients with Chronic Limb Ischemia Presented at Midwestern Vascular Conference
-Researchers concluded that in the clinical study the HAV was a safe, resilient, and effective…
Results From Mayo Clinic Clinical Study of Humacyte’s Human Acellular Vessel™ (HAV™) in Treatment of Patients with Chronic Limb Ischemia Presented at Midwestern Vascular Conference
-Researchers concluded that in the clinical study the HAV was a safe, resilient, and effective…
SalioGen Therapeutics Appoints Jason F. Cole as Chief Executive Officer and Chairman of the Board of Directors
Biotech industry veteran strengthens leadership team with decades of experience LEXINGTON, Mass., Sept. 11, 2023…
SalioGen Therapeutics Appoints Jason F. Cole as Chief Executive Officer and Chairman of the Board of Directors
Biotech industry veteran strengthens leadership team with decades of experience LEXINGTON, Mass., Sept. 11, 2023…